Company Overview
Company Type: Public Company
Website: www.cybin.com
Number of Employees: 50
Ticker: CYBN (NYSEAM)
Year Founded: -


Business Description
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
185.1
EBITDA
(50.6)
Total Enterprise Value
175.5
TEV/EBITDA
NM
EBIT
(50.8)
Cash & ST Invst.
9.3
P/Diluted EPS Before Extra
NM
Net Income
(48.9)
Total Debt
0.0
Price/Tang BV
16.9x
Capital Expenditure
0.0
Total Assets
45.7
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023


Estimates Snapshot (Current Fiscal Year End: Mar-31-2024 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.05)
(0.04)
(0.20)
(0.19)
(0.20)
Revenue (mm)
0.00
0.00
0.00
0.00
0.00
EBITDA (mm)
(12.65)
(12.80)
(51.10)
(56.55)
(52.46)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/EBITDA
NM
P/BV
5.51x

Non-Periodic Estimates

Recommendation
Buy (1.25)
Target Price
7.44
Potential Upside
863.93%


Key Professionals
Name
Title
So, Eric 
Co-Founder, President & Executive Chairman
Drysdale, Douglas L.
Chief Executive Officer
Glavine, Paul 
Co-Founder, Chief Growth Officer & Director
Kanakis, John 
Co-Founder
Cavers, Greg 
Chief Financial Officer
Bartlone, Aaron 
Chief Operating Officer
Nivorozhkin, Alex L.
Chief Scientific Officer
Challenger, Lori 
Chief Compliance, Ethics & Administrative Officer
Fahel, Gabriel 
Chief Legal Officer & Corporate Secretary
Somerset, Sara Brittany
Chief Communications Officers
Andrews, James 
Chief Cultivation & Extraction Officer
Avery, Kenneth 
Senior VP of Chemistry & Manufacturing

Key Board Members
Name
Title
So, Eric 
Co-Founder, President & Executive Chairman
Glavine, Paul 
Co-Founder, Chief Growth Officer & Director
Froese, Grant B.
Independent Director
Hoskins, Eric William
Independent Director
Lawson, Mark 
Independent Director
Firestone, Theresa S.
Lead Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
100 King Street West Suite 5600 | Toronto, ON | M5X 1C9 | Canada

Current and Pending Investors
Grey House Partners GP Inc., Innovating Capital (Pen King), LifeSci Venture Partners, Lincoln Park Capital, LLC (Pending), Negev Capital, Subversive Capital LLC, TCF Management LLC

Prior Investors
Noetic Fund

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.77
Market Cap (mm)
185.1
Open
 0.73
Shares Out. (mm)
240.0
Previous Close
 0.77
Float %
79.2%
Change on Day
0.04
Shares Sold Short (mm)
5.2
Change % on Day
5.4%
Dividend Yield %
-
Day High/Low
 0.77/ 0.72
Diluted EPS Excl. Extra Items
(0.26)
52 wk High/Low
 0.98/ 0.29
P/Diluted EPS Before Extra
NM
Volume (mm)
2.21
Avg 3M Dly Vlm (mm)
4.15
Beta 5Y
1.60


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
NYSEAM:CYBN - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Small Pharma Inc. (TSXV:DMT) (Pending)
Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company’s product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage. Its preclinical stage programs include SPL029, an oral formulation of a tryptamine to treat depressive disorder. The company is headquartered in London, the United Kingdom.

Europe
Pharmaceuticals
0.00
11.00
0.00
Adelia Therapeutics, Inc
Adelia Therapeutics, Inc, a biopharmaceutical company, develops a drug discovery platform for the development of proprietary psychedelics-based therapeutics. The company was incorporated in 2020 and is based in Fitchburg, Massachusetts.

United States and Canada
Biotechnology
-
-
-
Clarmin Explorations Inc.
As of November 5, 2020, Clarmin Explorations Inc. was acquired by Cybin Corp., in a reverse merger transaction. Clarmin Explorations Inc. engages in the exploration and development of mineral properties in Canada. The company holds 100% interest in the Benton property covering an area of 1,285 hectares located in the New Brunswick. The company was founded in 2016 and is headquartered in Vancouver, Canada.

United States and Canada
Pharmaceuticals
-
0.00
0.00
2762898 Ontario Inc.

United States and Canada
-
-
-
-
Cybin IRL Limited

Europe
-
-
-
-
Natures Journey, Inc

United States and Canada
-
-
-
-
Serenity Life Sciences Inc

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-28-2023
-
Merger/Acquisition
Buyer
Small Pharma Inc. (TSXV:DMT)
Cybin Inc. (NYSEAM:CYBN)
ACF Investors
23.85
Aug-23-2023
-
Public Offering
Target
Cybin Inc. (NYSEAM:CYBN)


35.00
Aug-18-2023
-
Shelf Registration
Target
Cybin Inc. (NYSEAM:CYBN)


118.06
Aug-17-2023
-
Public Offering
Target
Cybin Inc. (NYSEAM:CYBN)
Lincoln Park Capital, LLC Buyer Funds:Lincoln Park Capital Fund, LLC

30.00
Aug-17-2023
-
Shelf Registration
Target
Cybin Inc. (NYSEAM:CYBN)


160.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-03-2023
Product-Related Announcements
Cybin Inc. Completes Dosing in Phase 2 Study of Cyb003 for the Treatment of Major Depressive Disorder
Sep-28-2023
Company Conference Presentations
Cybin Inc. Presents at Cantor Fitzgerald Annual Global Healthcare Conference 2023, Sep-28-2023 01:15 PM
Sep-26-2023
Client Announcements
Cybin Inc. Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial
Sep-21-2023
Product-Related Announcements
Cybin Inc. Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder
Aug-28-2023
M&A Calls
Small Pharma Inc., Cybin Inc. - M&A Call

Competitors
Atai Life Sciences N.V. (NasdaqGM:ATAI), Awakn Life Sciences Corp. (NEOE:AWKN), COMPASS Pathways plc (NasdaqGS:CMPS), Filament Health Corp. (OTCPK:FLHL.F), Irwin Naturals, Inc. (CNSX:IWIN), Mind Medicine (MindMed) Inc. (NasdaqGS:MNMD), Numinus Wellness Inc. (TSX:NUMI), Reunion Neuroscience Inc.

M&A Advisors
Aird & Berlis LLP, Dorsey & Whitney LLP, Gowling WLG (Canada) LLP


Advisors
Most Recent Auditor
Zeifman & Company, LLP
M&A Advisors
Aird & Berlis LLP, Dorsey & Whitney LLP, Gowling WLG (Canada) LLP
Private Placement Advisors
Haywood Securities (USA) Inc., Stifel Nicolaus Canada Inc., VIII Capital Corp.
Public Offering Advisors
Aird & Berlis LLP, Dorsey & Whitney LLP, Dorsey & Whitney LLP, Zeifmans LLP


Most Recent Auditor
Zeifman & Company


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
H.C. Wainwright & Co.
Trucchio, Patrick Ralph
Oct 02, 2023 09:30 AM
CYBN
DMT Program Clears Another Hurdle; CYB003 Psychedelic in MDD on Track for Phase 2 Data in 4Q23; Reiterate Buy
Reports
7
ValuEngine, Inc.

Oct 02, 2023 03:42 AM
CYBN
ValuEngine Rating and Forecast Report for CYBN
Reports
11
Oppenheimer & Co. Inc.
Brisebois, François Daniel
Sep 21, 2023 07:50 AM
CYBN
CYB003 P2 Enrollment Completed, On Track for De-Risked Topline Readout in 4Q23
Notes
6
GlobalData

Sep 15, 2023 02:11 AM
CYBN
Cybin Inc (CYBN) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
73
GlobalData

Sep 13, 2023 04:08 AM
CYBN
Cybin Inc (CYBN) - Financial Analysis Review
Reports
196
Cantor Fitzgerald & Co.
Duncan, Charles Cliff
Sep 05, 2023 11:30 AM
CYBN
New dDMT IP Bolsters Pipeline Potential and May Create Value with P2 Efficacy Study, but Focus On dPsilo’ Data & P3 Plan
Notes
6
Canaccord Genuity
Kulkarni, Sumant Satchidanand
Sep 01, 2023 03:36 AM
CYBN
Getting big by buying Small; reiterate BUY
Reports
5
Oppenheimer & Co. Inc.
Brisebois, François Daniel
Aug 29, 2023 08:30 PM
CYBN
DMT Acquisition May Provide Key Synergies as CYBN Deepens Focus on Short Treatment Duration, Expecting Late 2023 Readouts
EPS Estimates*
6
H.C. Wainwright & Co.
Trucchio, Patrick Ralph
Aug 29, 2023 09:20 AM
CYBN
Acquires Small Pharma, Strengthening IP Position in Short-Acting Psychedelics; Reiterate Buy
Reports
7
Cantor Fitzgerald & Co.
Duncan, Charles Cliff
Aug 28, 2023 04:10 PM
CYBN
Takes Deu to Tango - Consolidation in Deu-DMT Space Does Not Make Us Depressed, May Move Clinical Programs Forward
Notes
6


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Point72 Asset Management, L.P.

18,950,000

7.90

13.9

Sep-14-2023


So L.L.B., LLB, Eric 

11,572,411

4.82

8.5

Sep-13-2023


Glavine, Paul 

10,492,407

4.37

7.7

Sep-13-2023


Nivorozhkin Ph.D., Alex L.

3,500,454

1.46

2.6

Jun-29-2023


Mirae Asset Global Investments Co., Ltd.

2,927,411

1.22

2.1

Sep-30-2023


Greene, Brett J.

2,887,222

1.20

2.1

Mar-14-2023


AdvisorShares Investments, LLC

2,162,636

0.90

1.6

Jun-30-2023


Raycroft, Rachel 

750,000

0.31

0.5

Sep-13-2023


Bartlone, Aaron 

701,070

0.29

0.5

Jun-29-2023


Simplify Asset Management Inc.

500,000

0.21

0.4

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Point72 Asset Management, L.P.
18,950,000
18,950,000
So L.L.B., LLB, Eric 
11,572,411
2,000,000
Mirae Asset Global Investments Co., Ltd.
2,927,411
1,079,425
FNY Investment Advisers, LLC
140,000
140,000
Interocean Capital Group, LLC
100,000
100,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Morgan Stanley, Investment Banking and Brokerage Investments
57,604
(2,600,000)
Palfreyman D.Sc., MRPharmS, Ph.D., Michael Gavin
0
(965,488)
Citadel Advisors LLC
0
(374,553)
Belpointe Asset Management LLC
0
(313,705)
Virtu Financial LLC, Asset Management Arm
0
(144,148)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
CYB003 (Future), CYB004 (Future), Patient Digital Therapy Platform (Future), Phenethylamine (Future), Psilocybin (Future), Psychedelic Compounds (Future), Psychedelic Tryptamine (Future), Tryptamine Derivatives (Future)


Upcoming Events
Date/Time
Type
Oct-10-2023
Company Conference Presentations
Oct-10-2023
Conferences
Oct-11-2023
Conferences
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-06-2023
Oct-06-2023
Cybin Inc. (NYSEAM:CYBN)
SEC
6-K
54 KB
Oct-06-2023
-
Cybin Inc. (NYSEAM:CYBN)
SEDAR
News Releases
383 KB
Oct-04-2023
Oct-04-2023
Cybin Inc. (NYSEAM:CYBN)
SEC
6-K
38 KB
Oct-04-2023
-
Cybin Inc. (NYSEAM:CYBN)
SEDAR
News Releases
70 KB
Oct-03-2023
Oct-03-2023
Cybin Inc. (NYSEAM:CYBN)
SEC
6-K
53 KB
Oct-03-2023
-
Cybin Inc. (NYSEAM:CYBN)
SEDAR
News Releases
457 KB
Sep-27-2023
Sep-27-2023
Cybin Inc. (NYSEAM:CYBN)
SEC
6-K
68 KB
Sep-27-2023
Sep-26-2023
Cybin Inc. (NYSEAM:CYBN)
SEC
6-K
48 KB
Sep-27-2023
-
Cybin Inc. (NYSEAM:CYBN)
SEDAR
News Releases
530 KB
Sep-26-2023
-
Cybin Inc. (NYSEAM:CYBN)
SEDAR
News Releases
293 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Greene, Brett J. (Former Chief Innovation Officer)
Mar-14-2023
Common Shares
2,387,222
-
Derivative Exercise and Retained Stock
477.44
Multiple
Palfreyman D.Sc., MRPharmS, Ph.D., Michael Gavin (Former Chief Research & Development Officer)
Jan-12-2023
Common Shares
585,258
-
Derivative Exercise and Retained Stock
153.92
Multiple
Nivorozhkin Ph.D., Alex L. (Chief Scientific Officer)
Jan-12-2023
Common Shares
2,246,094
-
Derivative Exercise and Retained Stock
179.06
Multiple
Greene, Brett J. (Former Chief Innovation Officer)
Jan-12-2023
Common Shares
500,000
-
Derivative Exercise and Retained Stock
New
Multiple
Hoskins, Eric William (Independent Director)
Jun-30-2022
Common Shares
100,000
76,988
Open Market Acquisition
New
Multiple
-
Jun-30-2022
Common Shares
50,000
38,494
Open Market Acquisition
-
Exchange Announcement
-
Jun-30-2022
Common Shares
50,000
38,494
Open Market Acquisition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
So, Eric 
Co-Founder, President & Executive Chairman
-
-

Glavine, Paul 
Co-Founder, Chief Growth Officer & Director
-
-

Froese, Grant B.
Independent Director
-
-

Hoskins, Eric William
Independent Director
-
-

Lawson, Mark 
Independent Director
(647) 302-0393
-
mark@lawson.net
Firestone, Theresa S.
Lead Independent Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
So, Eric 
Co-Founder, President & Executive Chairman
-
-

Drysdale, Douglas L.
Chief Executive Officer
-
604 684 0642
doug@cybin.com
Glavine, Paul 
Co-Founder, Chief Growth Officer & Director
-
-

Kanakis, John 
Co-Founder
-
-
John@cybin.com
Cavers, Greg 
Chief Financial Officer
-
-

Bartlone, Aaron 
Chief Operating Officer
-
-

Nivorozhkin, Alex L.
Chief Scientific Officer
-
-

Challenger, Lori 
Chief Compliance, Ethics & Administrative Officer
-
-

Fahel, Gabriel 
Chief Legal Officer & Corporate Secretary
-
-

Somerset, Sara Brittany
Chief Communications Officers
-
-
sarabrittany@cybin.com
Andrews, James 
Chief Cultivation & Extraction Officer
-
-

Avery, Kenneth 
Senior VP of Chemistry & Manufacturing
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
